Guggenheim analyst Subbu Nambi raised the firm’s price target on Illumina (ILMN) to $170 from $144 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $150 from $130 at Canaccord
- Illumina secures CMS reimbursement for TruSight in vitro cancer test
- Illumina price target raised to $155 from $135 at Stifel
- Illumina: Rich Valuation Amid Mounting Competitive and Execution Risks Supports Sell Rating
- Cathie Wood Doubles Down on High-Potential Biotech Plays